These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24598155)

  • 1. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
    Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
    J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    Qian H; Chi C; Tricard T; Zhu Y; Dong L; Wang Y; Sha J; Wang J; Ma Z; Wang Y; Liu J; Dong B; Pan J; Xue W
    J Urol; 2024 May; 211(5):648-655. PubMed ID: 38591703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.
    Chi C; Fan L; Dong B; Zhu Y; Xin Z; Pan J; Xue W
    Clin Genitourin Cancer; 2021 Aug; 19(4):e223-e234. PubMed ID: 33824096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
    Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
    Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
    Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
    Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
    Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
    Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
    Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
    McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
    Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
    Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
    Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
    Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
    Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
    Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
    Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
    Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
    Garzotto M; Higano CS; O'Brien C; Rademacher BL; Janeba N; Fazli L; Lange PH; Lieberman S; Beer TM
    Cancer; 2010 Apr; 116(7):1699-708. PubMed ID: 20143429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
    Thalgott M; Rack B; Horn T; Heck MM; Eiber M; Kübler H; Retz M; Gschwend JE; Andergassen U; Nawroth R
    Anticancer Res; 2015 Oct; 35(10):5679-85. PubMed ID: 26408743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
    Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
    World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.